RS20070078A - Inactivated poliomyelitis vaccine derived from sabin strain of polio virus - Google Patents

Inactivated poliomyelitis vaccine derived from sabin strain of polio virus

Info

Publication number
RS20070078A
RS20070078A RSP-2007/0078A RSP20070078A RS20070078A RS 20070078 A RS20070078 A RS 20070078A RS P20070078 A RSP20070078 A RS P20070078A RS 20070078 A RS20070078 A RS 20070078A
Authority
RS
Serbia
Prior art keywords
meningitis
hepatitis
vaccine
sabin strain
polio virus
Prior art date
Application number
RSP-2007/0078A
Other languages
English (en)
Inventor
Rajesh JAIN
Anil Chawla
Ganesh Kumraj
Original Assignee
Panacea Biotec Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd., filed Critical Panacea Biotec Ltd.,
Publication of RS20070078A publication Critical patent/RS20070078A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Proizvedena je inaktivirana Polio Vakcina nastala iz Sabinovog soja, koja se koristi za sigurnu i efikasnu imunizaciju protiv Poliomijelitisa. Takođe je obezbeđen i postupak za dobijanje takve vakcine i njenih formulacija. Davanje vakcine iz ovog pronalaska zajedno sa drugim antigenima obezbeđuje imunizaciju ne samo protiv polio infekcije, već takođe protiv drugih patogena koji prouzrokuju Hepatitis C, Hepatitis D, Hepatitis E, Meningitis A, Meningitis B, Meningitis C, Meningitis W, Meningitis Y, Pneumococcal (23 valentni ili više), Male boginje, Tifus, Bacil Calmette Guerin, Tuberkulozu, Humani imunodeficijentni virus, Antraks, ili slično, kojima su podložna deca i odrasli koji nisu prethodno imunizovani, a naročito deca
RSP-2007/0078A 2004-08-27 2004-08-27 Inactivated poliomyelitis vaccine derived from sabin strain of polio virus RS20070078A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000267 WO2007007344A1 (en) 2004-08-27 2004-08-27 Inactivated poliomyelitis vaccine derived from sabin strain of polio virus

Publications (1)

Publication Number Publication Date
RS20070078A true RS20070078A (en) 2008-11-28

Family

ID=34958659

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2007/0078A RS20070078A (en) 2004-08-27 2004-08-27 Inactivated poliomyelitis vaccine derived from sabin strain of polio virus

Country Status (7)

Country Link
US (1) US20080193478A1 (sr)
EP (1) EP1793852A1 (sr)
BR (1) BRPI0419023A (sr)
EA (1) EA010057B1 (sr)
MX (1) MX2007002372A (sr)
RS (1) RS20070078A (sr)
WO (1) WO2007007344A1 (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200902155B (en) 2006-09-29 2010-06-30 Japan Poliomyelitis Res Inst IPV-DPT vaccine
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EA020563B1 (ru) 2009-07-16 2014-12-30 Круселл Холланд Б.В. Получение полиовируса с высокими титрами для получения вакцины
CN103442730B (zh) * 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
EP2793939A1 (en) * 2011-12-23 2014-10-29 Novartis AG Stable compositions for immunising against staphylococcus aureus
EA201891945A3 (ru) * 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
WO2014204303A2 (en) * 2013-06-17 2014-12-24 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Methods for the prevention of aggregation of viral components
EP3157556B1 (en) 2014-06-17 2019-10-23 Janssen Vaccines & Prevention B.V. Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains
EP3172317B1 (en) 2014-07-24 2019-05-01 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
KR102219638B1 (ko) * 2014-10-07 2021-02-23 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 엔테로바이러스 불활화 및 보강제 흡착 방법과 이로부터 수득되는 저용량 백신 조성물
EP3703741A1 (en) 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
BR112020009960A2 (pt) 2017-11-30 2020-11-10 Takeda Vaccines, Inc. método para a inativação de vírus zika e métodos relacionados
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN115697397A (zh) * 2020-04-11 2023-02-03 谢七一 接种脊髓灰质炎疫苗对抗冠状病毒
US20210322542A1 (en) * 2020-04-11 2021-10-21 Qiyi Xie Vaccination against coronavirus with poliomyelitis vaccine

Also Published As

Publication number Publication date
BRPI0419023A (pt) 2007-12-11
EA200700496A1 (ru) 2007-10-26
MX2007002372A (es) 2007-05-08
EP1793852A1 (en) 2007-06-13
US20080193478A1 (en) 2008-08-14
EA010057B1 (ru) 2008-06-30
WO2007007344A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
RS20070078A (en) Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
PL2097102T3 (pl) Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2007056266A3 (en) Cd40 ligand fusion protein vaccine
TW200722101A (en) Novel composition
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
EP1504112A4 (en) DEVELOPMENT OF A VACCINE FOR THE PREVENTION OF INFECTIONS WITH THE FILOVIRUS IN PRIMATES
PL1796717T3 (pl) Szczepionka skojarzona
JP2009514840A5 (sr)
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
MX2010006984A (es) Vacunas contra la malaria.
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
WO2003059385A3 (en) Hiv vaccine and method of use
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
WO2006045532A3 (en) Virosome particles comprising antigens from influenza virus and hepatitis b virus
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
AU6365301A (en) Vaccine
WO2005097179A3 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih.
NO20016211D0 (no) Forhindring av diabetes type 1 og andre ikke-polio enterovirus-sykdommer
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
WO2003032917A3 (en) Hookworm vaccine
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
WO2005117956A3 (en) Neisserial vaccines